Optimizing functional synergies between local and systemic memory CD4 T cell responses to influenza
优化局部和全身记忆 CD4 T 细胞对流感反应之间的功能协同作用
基本信息
- 批准号:10317117
- 负责人:
- 金额:$ 18.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-12-10 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:Activities of Daily LivingAdoptive TransferAffectAntigen PresentationAntigensAntiviral ResponseCD4 Positive T LymphocytesCellsCellular ImmunityCharacteristicsCombined VaccinesDataEmigrationsExperimental ModelsFutureGenetic TranscriptionGenotypeGoalsHeterogeneityImmuneImmunityInfectionInflammationInflammatoryInfluenzaInfluenza A virusLungMediatingMemoryModelingMorbidity - disease rateMusOutcomePathway interactionsPattern RecognitionPhasePopulationProductionRouteSecondary toSiteStructure of parenchyma of lungSystemT cell responseTestingTissuesUncertaintyVaccinatedVaccinationVaccine DesignVaccinesViralViral PhysiologyVirusVirus DiseasesWorkcell typecombatdesignglobal healthimmunopathologyimprovedimproved outcomeinflammatory milieuinfluenza infectioninfluenza virus vaccineinnovationinsightmemory CD4 T lymphocytememory recallneutralizing antibodynovelnovel vaccinespathogenreconstitutionresponsesecondary lymphoid organsynergismvaccine-induced immunity
项目摘要
Summary/Abstract
Protective memory CD4 T cell responses against influenza A virus (IAV) involve a diverse array of cell types
with unique characteristics. An emerging axis of heterogeneity is the division between lung tissue-resident
memory (TRM) and conventional memory cells that circulate through secondary lymphoid organs. Most studies
to date have focused on characterizing the anti-viral activities of these subsets in isolation during recall
responses. Our preliminary studies, however, support the concept that synergies between regional and systemic
memory cells are a vital and uncharacterized aspect of highly effective CD4 T cell responses. Our work also
indicates that such integrated responses can be optimized to improve viral control and to reduce
immunopathology by promoting different functions in TRM versus in conventional memory CD4 cells. This
proposal will provide novel mechanistic insight into how vaccines can maximize synergies between local and
systemic CD4 memory cells to improve vaccine-induced protection against IAV.
We will optimize models to reconstitute naive mice with separate populations of well characterized lung TRM
and/or conventional memory CD4 cells primed by IAV. This experimental system will facilitate clear analysis of
how TRM responses impact the re-activation and subsequent response parameters of systemic memory CD4
cells upon IAV infection. Our models will also allow for modulation of the numbers and functional capacities of
the cells within each memory compartment in order to identify unique subset-specific correlates of protection.
We will also specifically deplete CD4 TRM in IAV-immune mice, thus allowing further characterization of local and
systemic memory CD4 synergy during heterosubtypic infection in intact, vaccinated mice.
In Aim 1, we will test the hypothesis that lung CD4 TRM activation within the first few days of IAV infection
increases efficiency of antigen presentation in secondary lymphoid organs, leading to the more rapid recall of
conventional memory CD4 cells. We will also determine if TRM reduce the magnitude of conventional memory
responses through their earlier control of viral titers and inflammation in the lung. In Aim 2, we will determine
how the integrated memory CD4 response affects key parameters of IAV clearance and collateral damage
versus in mice reconstituted with either memory subset alone. Finally, we will determine if synergistic CD4
protection against IAV can be improved by restricting prototypical T-bet-dependent Th1 programming to only the
TRM subset. This work will provide a mechanistic framework to improve CD4 T cell-dependent protection against
IAV and other pathogens and optimize innovative experimental systems to facilitate future discovery.
摘要/摘要
针对甲型流感病毒(IAV)的保护性记忆CD4T细胞反应涉及多种细胞类型
具有独特的特点。异质性的一个新轴心是肺组织驻留在
记忆(TRM)和通过次级淋巴器官循环的常规记忆细胞。大多数研究
到目前为止,他们的重点是在召回过程中孤立地表征这些亚群的抗病毒活性
回应。然而,我们的初步研究支持这样一个概念,即区域和系统之间的协同作用
记忆细胞是高效的CD4T细胞反应的一个重要且未被描述的方面。我们的工作也
表明这种综合反应可以被优化,以改善病毒控制并减少
通过促进TRM与传统记忆CD4细胞中不同功能的免疫病理学。这
该提案将为疫苗如何最大限度地发挥本地和
系统的CD4记忆细胞,以提高疫苗诱导的对IAV的保护。
我们将优化模型以重建具有良好特征的肺TRM的不同种群的幼小鼠
和/或IAV激活的常规记忆CD4细胞。这一实验系统将有助于清楚地分析
TRM反应如何影响系统记忆CD4的再激活和后续反应参数
细胞感染IAV。我们的模型还将允许调整数字和功能容量
每个记忆隔间内的细胞,以便识别保护的独特子集特定关联。
我们还将在IAV免疫的小鼠中特异性地耗尽CD4TRM,从而允许进一步表征局部和
完整的免疫小鼠异亚型感染期间的系统记忆CD4协同作用。
在目标1中,我们将检验这样一种假设,即在IAV感染的最初几天内,肺内CD4TRM激活
提高次级淋巴器官的抗原呈递效率,导致更快地回忆起
常规记忆的CD4细胞。我们还将确定TRM是否会降低传统内存的大小
通过早期对病毒滴度和肺部炎症的控制而产生反应。在目标2中,我们将确定
整合记忆的CD4反应如何影响IAV清除和附带损伤的关键参数
而不是只用任一记忆子集重建的小鼠。最后,我们将确定协同作用的CD4是否
对IAV的保护可以通过限制原型T-bet依赖的Th1编程仅限于
TRM子集。这项工作将提供一个机制框架,以提高对CD4T细胞依赖的保护
IAV和其他病原体,并优化创新的实验系统,以促进未来的发现。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Regulation of CD4 T Cell Responses by the Transcription Factor Eomesodermin.
- DOI:10.3390/biom12111549
- 发表时间:2022-10-24
- 期刊:
- 影响因子:5.5
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Karl Kai McKinstry其他文献
Karl Kai McKinstry的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Karl Kai McKinstry', 18)}}的其他基金
Harnessing type I interferon to promote lung-resident memory CD4 T cell immunity against influenza
利用I型干扰素促进肺驻留记忆CD4 T细胞对流感的免疫
- 批准号:
10650859 - 财政年份:2022
- 资助金额:
$ 18.64万 - 项目类别:
Harnessing type I interferon to promote lung-resident memory CD4 T cell immunity against influenza
利用I型干扰素促进肺驻留记忆CD4 T细胞对流感的免疫
- 批准号:
10417904 - 财政年份:2022
- 资助金额:
$ 18.64万 - 项目类别:
Control of CD4 T cell effector function and tissue-resident memory fate by the transcription factor Eomes
转录因子 Eomes 控制 CD4 T 细胞效应功能和组织驻留记忆命运
- 批准号:
9807682 - 财政年份:2019
- 资助金额:
$ 18.64万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 18.64万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 18.64万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 18.64万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 18.64万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 18.64万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 18.64万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 18.64万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 18.64万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 18.64万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 18.64万 - 项目类别: